Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand

Thanate Dajsakdipon, Thiti Susiriwatananont, Concord Wongkraisri, Suthinee Ithimakin, Napa Parinyanitikul, Archara Supavavej, Arunee Dechaphunkul, Patrapim Sunpaweravong, Sunee Neesanun, Charuwan Akewanlop, Thitiya Dejthevaporn, Unknown

Open source

DOI: 10.1186/s12885-024-12765-x
Published: 2024-08-16
Container: BMC Cancer
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12885-024-12765-x,
  title = {Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand},
  author = {Thanate Dajsakdipon and Thiti Susiriwatananont and Concord Wongkraisri and Suthinee Ithimakin and Napa Parinyanitikul and Archara Supavavej and Arunee Dechaphunkul and Patrapim Sunpaweravong and Sunee Neesanun and Charuwan Akewanlop and Thitiya Dejthevaporn and Unknown},
  year = {2024},
  journal = {BMC Cancer},
  doi = {10.1186/s12885-024-12765-x},
  url = {https://doi.org/10.1186/s12885-024-12765-x}
}

RIS

TY  - JOUR
TI  - Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand
AU  - Thanate Dajsakdipon
AU  - Thiti Susiriwatananont
AU  - Concord Wongkraisri
AU  - Suthinee Ithimakin
AU  - Napa Parinyanitikul
AU  - Archara Supavavej
AU  - Arunee Dechaphunkul
AU  - Patrapim Sunpaweravong
AU  - Sunee Neesanun
AU  - Charuwan Akewanlop
AU  - Thitiya Dejthevaporn
AU  - Unknown
PY  - 2024
JO  - BMC Cancer
DO  - 10.1186/s12885-024-12765-x
UR  - https://doi.org/10.1186/s12885-024-12765-x
ER  -

APA

Dajsakdipon, T., Susiriwatananont, T., Wongkraisri, C., Ithimakin, S., Parinyanitikul, N., Supavavej, A., Dechaphunkul, A., Sunpaweravong, P., Neesanun, S., Akewanlop, C., Dejthevaporn, T., & Unknown (2024). Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand. BMC Cancer. https://doi.org/10.1186/s12885-024-12765-x

Source records

crossref · retrieved 2026-09-26T10:37:46.893Z